Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsCannabis Has Been Studied More Than Many FDA Approved Pharmaceuticals
HIGH TIMES
By Paul Armentano · Fri Jan 24, 2014
Opponents of legalizing cannabis for medicinal purposes are fond of arguing that the plant must be subjected to the same standards of clinical study and FDA review as conventional medicines. What they fail to mention is that cannabis and its active components have already been subjected to a greater degree of scientific scrutiny than many FDA-approved pharmaceuticals.
According to a just-published analysis of some 200 newly FDA-approved medications, few conventional drugs are tested in multiple, large-scale clinical assessing safety and efficacy trials prior to market approval. {A}bout a third won approval on the basis of a single clinical trial, and many other trials involved small groups of patients and shorter durations, reports The Washington Post in its summary of the study, which appears in the January edition of The Journal of the American Medical Association. Only about 40 percent of approvals included trials in which the new drug was compared with existing drugs on the market.
By comparison, there exists over 20,000 published studies or reviews in the scientific literature referencing the cannabis plant and its cannabinoids, nearly half of which were published within the last five years, according to a keyword search on PubMed Central, the government repository for peer-reviewed scientific research. Of these, more than 100 are controlled clinical trials assessing the therapeutic efficacy of cannabinoids for a variety of indications.
A 2006 review of 72 of these trials, conducted between the years 1975 and 2004, identifies ten distinct pathologies for which controlled studies on cannabinoids have been published. The review concludes that these trial data affirm that cannabinoids exhibit an interesting therapeutic potential as anti-emetics, appetite stimulants in debilitating diseases (cancer and AIDS), analgesics, as well as in the treatment of multiple sclerosis, spinal cord injuries, Tourette syndrome, epilepsy and glaucoma.
MORE
By Paul Armentano · Fri Jan 24, 2014
Opponents of legalizing cannabis for medicinal purposes are fond of arguing that the plant must be subjected to the same standards of clinical study and FDA review as conventional medicines. What they fail to mention is that cannabis and its active components have already been subjected to a greater degree of scientific scrutiny than many FDA-approved pharmaceuticals.
According to a just-published analysis of some 200 newly FDA-approved medications, few conventional drugs are tested in multiple, large-scale clinical assessing safety and efficacy trials prior to market approval. {A}bout a third won approval on the basis of a single clinical trial, and many other trials involved small groups of patients and shorter durations, reports The Washington Post in its summary of the study, which appears in the January edition of The Journal of the American Medical Association. Only about 40 percent of approvals included trials in which the new drug was compared with existing drugs on the market.
By comparison, there exists over 20,000 published studies or reviews in the scientific literature referencing the cannabis plant and its cannabinoids, nearly half of which were published within the last five years, according to a keyword search on PubMed Central, the government repository for peer-reviewed scientific research. Of these, more than 100 are controlled clinical trials assessing the therapeutic efficacy of cannabinoids for a variety of indications.
A 2006 review of 72 of these trials, conducted between the years 1975 and 2004, identifies ten distinct pathologies for which controlled studies on cannabinoids have been published. The review concludes that these trial data affirm that cannabinoids exhibit an interesting therapeutic potential as anti-emetics, appetite stimulants in debilitating diseases (cancer and AIDS), analgesics, as well as in the treatment of multiple sclerosis, spinal cord injuries, Tourette syndrome, epilepsy and glaucoma.
MORE
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
2 replies, 712 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (4)
ReplyReply to this post
2 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Cannabis Has Been Studied More Than Many FDA Approved Pharmaceuticals (Original Post)
DeSwiss
Feb 2015
OP
Yes but they haven't found anything really horrible about it yet so they must keep trying
Fumesucker
Feb 2015
#2
In_The_Wind
(72,300 posts)1. IMO: It's only a matter of time before it becomes legal in most states.
[img][/img] [img][/img] [img][/img]
Fumesucker
(45,851 posts)2. Yes but they haven't found anything really horrible about it yet so they must keep trying
If at first you don't succeed, try try again..